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Abstract
Background: Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by parkinsonism,
cerebellar ataxia and autonomic dysfunction. Pathogenic mechanisms remain obscure but the neuropathological hallmark
is the presence of a-synuclein-immunoreactive glial cytoplasmic inclusions. Genetic variants of the a-synuclein gene, SNCA,
are thus strong candidates for genetic association with MSA. One follow-up to a genome-wide association of Parkinson’s
disease has identified association of a SNP in SNCA with MSA.
Methodology/Findings: We evaluated 32 SNPs in the SNCA gene in a European population of 239 cases and 617 controls
recruited as part of the Neuroprotection and Natural History in Parkinson Plus Syndromes (NNIPPS) study. We used 161
independently collected samples for replication. Two SNCA SNPs showed association with MSA: rs3822086 (P= 0.0044), and
rs3775444 (P= 0.012), although only the first survived correction for multiple testing. In the MSA-C subgroup the association
strengthened despite more than halving the number of cases: rs3822086 P= 0.0024, OR 2.153, (95% CI 1.3–3.6); rs3775444
P= 0.0017, OR 4.386 (95% CI 1.6–11.7). A 7-SNP haplotype incorporating three SNPs either side of rs3822086 strengthened
the association with MSA-C further (best haplotype, P= 8.761024). The association with rs3822086 was replicated in the
independent samples (P= 0.035).
Conclusions/Significance: We report a genetic association between MSA and a-synuclein which has replicated in
independent samples. The strongest association is with the cerebellar subtype of MSA.
Trial Registration: ClinicalTrials.gov NCT00211224.
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Introduction
Multiple system atrophy (MSA) is a rare progressive neurodegen-
erative disease characterized by parkinsonism, cerebellar dysfunction
and dysautonomia corresponding to previous diagnostic appellations
of striatonigral degeneration, olivopontocerebellar atrophy and Shy-
Drager syndrome. Estimates of age-adjusted prevalence vary between
1.9 and 4.4 per 100,000 persons although this may represent an
underestimate as post-mortem studies have suggested that as many as
5% of cases of clinically diagnosed Parkinson’s disease may in fact
have MSA. The converse is also true however, and in those recruited
as part of the Neuroprotection and Natural History in Parkinson’s
Plus Syndromes (NNIPPS) study, about 7% of patients diagnosed
with MSA at the start had a different diagnosis by the end [1].
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Pathologically, the hallmark of MSA is a-synuclein-immunore-
active glial cytoplasmic inclusions in oligodendrocytes throughout
the brain, associated with neuronal loss, loss of myelin, astrocytosis
and a marked microglial reaction most prominent in brain regions
involved in motor and supraspinal autonomic control. The
presence of a-synuclein-immunoreactive pathology, which places
MSA amongst the broad category of synucleinopathies including
Parkinson’s disease and dementia with Lewy bodies, suggests that
an abnormality of a-synuclein may play a role in the mechanisms
of cell death in MSA.
MSA is generally considered a sporadic condition. Indeed, the
diagnostic consensus criteria for MSA specifically mention a family
history of parkinsonism or ataxia as a feature not supportive of the
diagnosis [2]. Nonetheless, a few apparently familial cases have
been described [3–8]. There have been few studies on genetic
sequence variants in sporadic MSA [9–20] and no environmental
risk factors have been consistently identified in large samples. A
genetic association has now been identified between a gene variant
in the a-synuclein gene (SNCA, OMIM accession *163890;
Ensembl ENSG00000145335) and MSA [21].
We examined the association between SNCA variants and MSA
using the DNA Bank of the NNIPPS cohort [1]. This cohort has a
nearly 50% autopsy rate for MSA so that the criteria for diagnosis
can be validated pathologically, and in individual cases we can be
certain of the diagnosis. The NNIPPS diagnostic criteria for MSA
(Table 1) show excellent convergent validity with the investigators’
assessment of diagnostic probability (point-biserial correlation:
MSA rpb= 0.93, P,0.0001), and excellent predictive validity
against histopathology [sensitivity and specificity (95% CI); 0.96
(0.88–0.99) and 0.91 (0.86–0.93)] [1], so the sample is likely to
represent a more highly homogeneous diagnostic group than is
usually possible. For replication of results, we analyzed a
population of 78 pathologically verified cases from the Institute
of Neurology Brain Bank and 83 clinically defined samples from a
Parisian study (Table 2). We found that genetic variants of SNCA
were associated with MSA and more specifically, with the subset of
people who had cerebellar signs.
Methods
The protocol for this trial and supporting CONSORT checklist
are published elsewhere [1].
Ethics Statement
Patients gave informed written consent prior to inclusion in the
trial. Additional consent was obtained both for DNA sampling and
post-mortem brain tissue donation. The protocol was approved by
the Ethics Committees/Institutional Review Boards of each
coordinating centre in the three participating countries. The trial
was conducted according to International standards of Good
Clinical Practice-(ICH guidelines and the Helsinki Declaration).
Study Subjects
Subjects were recruited as part of the Neuroprotection and
Natural History in Parkinson’s Plus Syndromes (NNIPPS) study
using the NNIPPS diagnostic criteria which have been described
elsewhere together with the trial design, population description
and treatment results [1] (Table 1). The 239 cases and 617
controls in this study were of European ancestry and matched for
age (MSA mean age at sampling 62.84, control mean age 61.03)
(Table 2). The clinical diagnosis at the study end was used to
define MSA unless a pathological diagnosis was available. For
exploratory sub-group analysis, patients were stratified as MSA-P
or MSA-C based on the absence or presence of cerebellar signs at
entry. 11 cases and 14 controls had a low genotyping rate (,90%)
and were excluded from further analysis. 101 of the remaining
cases were in the MSA-C subgroup. 251 patients with progressive
supranuclear palsy (PSP) recruited within the same study were also
tested for MSA-associated SNPs to exclude a recruitment bias as
the explanation for any findings, as PSP is not a synucleinopathy
and we would not therefore expect an MSA-associated SNCA SNP
to be associated with PSP.
The NNIPPS study was an academic-led, multi-centre (UK,
France, Germany), phase III trial of riluzole in MSA and
progressive supranuclear palsy. Controls were recruited in the
UK from the neurologically normal spouses of participating
patients. In France and Germany, the controls were taken from
existing DNA banks of neurologically normal controls.
Replication study samples
The 78 MSA samples from the Institute of Neurology Brain
Bank (Table 2) fulfilled the consensus criteria for pathologically
proven MSA [2]. All were of UK ancestry. Of these, 68% had
cerebellar signs. Samples were derived from blood.
The MSA samples from Paris (Table 2) were collected
consecutively as part of a study on atypical Parkinsonism and
cerebellar ataxia. There were 44 cases with Probable MSA and 44
with Possible MSA as defined by the consensus criteria [2]. Of 88
samples, five were not of European ancestry and were therefore
excluded from further analysis. Of these, 85% had cerebellar signs
as the clinic specializes in cerebellar disease. Samples were derived
from blood.
Genotyping
32 SNPs in and around SNCAwere selected for association testing
with MSA (Figure 1, Table 3). In addition, we genotyped the multi-
allelic microsatellite repeat known as NACP-Rep1 which is situated
within the promoter region ,10 kbp upstream of the translational
Table 1. Summary of diagnostic criteria for MSA used in the NNIPPS study.
Inclusion criteria Exclusion criteria
All of: And at least one of: Any of:
Akinetic-rigid syndrome Symptomatic autonomic dysfunction Evidence of another neurological diagnosis
Age at onset at least 30 years old Cerebellar ataxia Evidence of a different cause for an akinetic-rigid
syndrome (eg drug side effect)
Disease duration 12 months to 8 years Postural instability or falls within 3 years of onset Dementia
Pyramidal signs
doi:10.1371/journal.pone.0007114.t001
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start point of SNCA at chromosome 4q21, using an ABI3130XL
Genotyper (Applied Biosystems) and Genotyper v4.0 software. This
complex microsatellite with sequence (TC)10–11TT(TC)8–11(TA)7–9
(CA)10–11 has been variably associated with PD [22,23] but not
MSA [12], although the numbers studied were small. There are five
common alleles, each differing in size by two nucleotides, the
greatest variability being in the CA portion with subsidiary
variability in the (TC)8–11(TA)7–9 portion. However, ex vivo
functional analysis suggests that the overall length of the
microsatellite rather than its sequence, determines transcriptional
regulation and hence SNCA gene expression [24]. We numbered the
alleles from 1 to 5 in order of increasing size.
For the NNIPPS samples, DNA was extracted from venous
blood samples collected into Li-heparin tubes by standard
methods. SNPs were genotyped independently of the study group
and blinded to case-control status by KBiosciences (Hoddesdon
Herts, EN11 0EX, UK; www.kbioscience.co.uk) using a patent-
protected competitive allele specific PCR system (KASPar) and
TaqmanTM.
The Institute of Neurology pathological samples were geno-
typed for rs3822086 using TaqmanTM assay (Applied Biosystems,
Forster City, CA, USA).
The 83 Paris samples were genotyped for the single nucleotide
polymorphism rs3822086 by sequencing in a single direction using
the BigDye Terminator Cycle Sequencing kit v3.1 (Applied
Biosystems, Forster City, CA, USA). Sequences were analysed
using Seqscape v2.5 software.
Statistical Analysis
Quality control. Tests for Hardy-Weinberg equilibrium were
performed for each SNP in controls using Fisher’s exact test. A
P-value,0.05 led to exclusion from further analysis. Tests for
systematically missing genotypes in either cases or controls were
performed to identify sample selection or genotyping problems
preferentially affecting either group. Tests for missingness by
genotypic status were also performed to identify errors relating to
difficulty calling certain genotypes. Associated SNPs were further
tested by looking for association in a tagging haplotype that
excluded the associated SNP to reduce the likelihood of an
artefactual association resulting from genotyping.
Power. Assuming a lifetime MSA risk of 1 in 1000, and for a
P-value close to the permutation corrected threshold of 0.05
(alpha = 0.005), there is 80% power to detect an odds ratio of 1.8
for a minor allele frequency (MAF) of 0.1, 1.6 for MAF 0.2 and 1.5
for MAF.0.2.
Imputation. Genotypes for SNPs genotyped in the CEU
HapMap sample but not in this study were imputed using
IMPUTE [25] with a threshold of 0.9 and default values for other
parameters. Subsequent analysis was performed in PLINK.
Association testing. SNP analyses were performed in PLINK
(http://pngu.mgh.harvard.edu/purcell/plink/) [26]. Samples were
tested for allelic association using the Mantel-Haenszel chi-squared
test, stratifying by country of origin. Odds ratios were tested for
homogeneity between countries using the Breslow-Day test.
Association testing by Pearson chi-squared test was performed for
the replication study to maximise numbers and therefore statistical
power. Controls were those used in the primary analysis.
Table 2. Demographic features of the samples used.
Sample type N Age at onset (SD) Age at sampling (SD) M:F ratio Proportion MSA-C
NNIPPS samples
MSA all 239 58.0 (8.43) 62.8 (8.25) 0.56 0.44
Pathological diagnosis 44 57.0 (8.41) 61.9 (7.94)
Clinical diagnosis 195 58.2 (8.44) 63.1 (8.32)
Controls 617 N/A 61.0 (12.9) 0.47 N/A
Replication samples
Paris Sample Bank 83 54.7 (8.67) 0.65
IoN Brain Bank 78 56.5 (10.0) 0.47
doi:10.1371/journal.pone.0007114.t002
Figure 1. The genetic architecture of the SNCA gene and the
markers genotyped. The base pair position along chromosome 4 is
shown by the top ruler. The position of the a-synuclein gene is shown
in the next row down, with exons represented by vertical lines and
introns by lines connecting them. The relative positions of the
genotyped markers are shown below, with vertical lines connecting
position to the linkage disequilibrium map. Asterisks show the two
markers demonstrating association in MSA-C. Only the left-most marker
showed association with MSA as a whole. (For a list of markers
genotyped and P-values, see Table 3). The coloured triangle is the
linkage disequilibrium heat map showing the strength of association
between pairs of markers as measured by D9. Red is high and blue low
with the other colours intermediate. The two associated SNPs are in
different linkage disequilibrium blocks and are not in linkage
disequilibrium with each other.
doi:10.1371/journal.pone.0007114.g001
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Multiple testing correction was performed using the Max(T)
permutation procedure implemented in PLINK permuted within
the strata of country of origin.
A multilocus genotype test examining whole gene association was
performed using step-wise permutation implemented in PLINK.
Microsatellite alleles were tested for association by x2 test using
the permutation procedure instituted in CLUMP to account for
the multiple ways that microsatellite alleles can be combined to
form two groups.
Results
SNP analyses
SNP rs356220 showed missing genotypes in nearly 18% of
controls compared with,1% of cases (P=4.73610215) suggesting
a systematic problem in genotyping of this SNP in control samples,
and it was therefore excluded from further analyses. The
remaining 31 SNPs were analysed for association with MSA.
Two SNPs showed association with MSA in the NNIPPS
samples: rs3822086 (P=0.0044), and rs3775444 (P=0.012)
(Table 3). Only rs3822086 survived multiple testing correction
for association with MSA (P=0.047). A step-wise whole gene
permutation test gave P=0.029 with the same two SNPs retained.
We repeated the analysis in the MSA-C subgroup for these two
SNPs and found the association strengthened despite more than
halving the number of cases: rs3822086 P=0.0024, OR 2.153,
(95% CI 1.3–3.6, Breslow-Day test for homogeneity, P=0.81);
rs3775444 P=0.0017, OR 4.386 (95% CI 1.6–11.7, Breslow-Day
test P=0.36); step-wise whole gene permutation test P=0.0084.
A haplotype of six surrounding SNPs was identified correlating
with rs3822086 at r2.0.5. Without rs3822086 included, this still
showed association at P=0.048, increasing confidence that the
association observed was not due to a genotyping artefact.
Including rs3822086 strengthened the association with MSA-C.
The most strongly associated haplotype, GGATGGT gave
P=8.761024, omnibus test P=0.027.
As expected, testing of rs3822086 and rs3775444 in PSP showed
no association, with unadjusted P-values of 0.112 and 0.242
respectively.
NACP-Rep1 Microsatellite analyses
Permutation-based CLUMP analysis showed no association
(P=0.094).
Replication analyses
The samples from the Institute of Neurology Brain Bank and
Paris confirmed association of rs3822086 with MSA (P=0.035)
with odds ratio 1.75 (95% C.I. 1.05–2.89).
Imputation analyses
After imputation of genotypes at ungenotyped SNPs there were
a total of 318 SNPs tested, with genotypes predicted at 97.2%
accuracy. SNP rs3822086 remained the most strongly associated
with MSA. An MSA-associated SNP identified in another study
[21], rs11931074, was also associated with MSA in this study
(P=0.025). For the MSA-C subgroup, rs3775444 and rs3822086
again remained the most strongly associated SNPs. As for the
SNPs in this study, rs11931074 was more strongly associated with
MSA-C than with MSA alone (P=0.0125).
Discussion
We have found two positive associations in the SNCA gene with
MSA, one with rs3822086 and the other with rs3775444, although
only one survives correction for multiple testing. The association is
significant because of the role of a-synuclein in the underlying
pathology of MSA. Because the phenotypic spectrum of MSA is
broad and the relative frequency of cerebellar and parkinsonian
presentations appears to be influenced by ethnicity [27] we
stratified our cases as MSA-C and MSA-P to explore possible
differences in association between these phenotypes in our sample.
We observed a stronger association of SNCA variants with MSA-C
than with MSA as a whole. This is intriguing and requires
exploration in other studies, but may indicate that interactions
between SNCA gene variants and other risk factors influence
phenotype in MSA.
Until recently, studies of polymorphisms of SNCA had failed to
demonstrate any association with MSA either by sequencing the
entire coding region in a small number of Japanese cases [11] or
by genotyping two microsatellite markers, one in the promoter and
the other an intron of SNCA in 47 cases from the UK [12,19]. A
study examining SNPs prioritized in a genome-wide association
study of Parkinson’s disease for follow-up testing in MSA has now
identified a strong association of homozygosity for the T allele of
SNP rs11931074 and MSA [21]. This SNP has a similar minor
allele frequency (0.056) to rs3822086 (0.058) and the two SNPs are
in strong linkage disequilibrium (D9 0.977, r2 0.922). It is therefore
not surprising that rs11931074 shows association with both MSA
and MSA-C in our study, although the association is not as strong
as for rs3822086. It would be of interest to impute rs3822086 in
the genome-wide association study samples to see if the stronger
association of this SNP persists in that sample set. Nevertheless,
this suggests that both rs3822086 and rs11931074 are tagging the
same functional genetic variation. Given that both have a
relatively low minor allele frequency, this may be a rare haplotype
or variant.
The associated variants we have identified are both intronic,
and neither is close to a splice site, nor are they predicted to
disrupt or alter splicing. They are not in intronic splice enhancer
sites, nor alternative cassette exons. They are not especially
conserved and are not obviously regulatory. It is therefore likely
that a different SNP tagged by these variants is the functional
variant, and this is further supported by the haplotypic association
we identified for SNPs surrounding rs3822086, which persists even
when this SNP is excluded.
There are several factors that could confound this study. For
example, population stratification can lead to false positive results.
We used three strategies to minimize this. Firstly, the samples were
all of European ancestry; secondly we stratified the primary
analysis by country of origin; and thirdly we replicated the findings
in an independent set of cases. The associated SNP survived
multiple testing correction, increasing confidence in the associa-
tion. Furthermore, the global gene-wise evidence for association
was significant and requires no further multiple testing correction
making a false positive result less likely. Phenotypic heterogeneity
was minimized by using validated clinical criteria with excellent
inter-observer agreements, and pathological verification where
possible. The possibility of bias inherent in the selection process for
enrolment to the NNIPPS study was excluded by testing the MSA-
associated SNP for association with the different disease PSP, also
using the NNIPPS study samples. PSP is not expected to have an
abnormality in the SNCA gene since it is not a synucleinopathy: no
association was detected. Systematic genotyping errors can lead to
false positive results, but we observed strict, comprehensive quality
control measures. Furthermore, a haplotype using a set of SNPs
surrounding the associated SNP and which correlated with the
genotype, also detected the association suggesting that this is not
an artefact at the tested SNP.
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Our findings show that genetic variation in the a-synuclein
gene is associated with sporadic MSA, and suggest that
susceptibility to MSA-C may be the greater risk of SNCA variation.
These results suggest that a-synuclein can play a primary role in
the pathogenesis of MSA.
Supporting Information
Appendix S1 The NNIPPS study Group
Found at: doi:10.1371/journal.pone.0007114.s001 (0.04 MB
DOC)
Acknowledgments
We thank the patients and their families for their commitment and
altruism, the DNA and cell bank of IFR 70 for sample preparation, and Dr.
Wilhelm Fischer.
The NNIPPS Genetic Study Group is listed in Appendix S1
Author Contributions
Conceived and designed the experiments: AAC AD NWW JSH KM YA
AB PNL GB. Performed the experiments: AAC MP AC AEMR. Analyzed
the data: AAC MP PNL GB. Contributed reagents/materials/analysis
tools: AD NWW BL AL AB. Wrote the paper: AAC AD NWW MP JSH
KM AB PNL GB. Logistic management: JSH. Quality assurance: JSH.
Responsible for repository management: KM. Logistic management of
German samples: SS. Coordinator for NNIPPS Germany: AL. Coordina-
tor for NNIPPS UK: PNL. Coordinator for NNIPPS France: GB.
References
1. Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, et al. (2009) Riluzole
treatment, survival and diagnostic criteria in Parkinson plus disorders: The
NNIPPS Study. Brain 132: 156–171.
2. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, et al. (2008) Second
consensus statement on the diagnosis of multiple system atrophy. Neurology 71:
670–676.
3. Lewis P (1964) Familial Orthostatic Hypotension. Brain 87: 719–728.
4. Nakazato Y, Yamazaki H, Hirato J, Ishida Y, Yamaguchi H (1990)
Oligodendroglial microtubular tangles in olivopontocerebellar atrophy.
J Neuropathol Exp Neurol 49: 521–530.
5. Costa C, Duyckaerts C, Cervera P, Hauw JJ (1992) [Oligodendroglial inclusions,
a marker of multisystemic atrophies]. Rev Neurol (Paris) 148: 274–280.
6. Wullner U, Abele M, Schmitz-Huebsch T, Wilhelm K, Benecke R, et al. (2004)
Probable multiple system atrophy in a German family. J Neurol Neurosurg
Psychiatry 75: 924–925.
7. Soma H, Yabe I, Takei A, Fujiki N, Yanagihara T, et al. (2006) Heredity in
multiple system atrophy. J Neurol Sci 240: 107–110.
8. Hara K, Momose Y, Tokiguchi S, Shimohata M, Terajima K, et al. (2007)
Multiplex families with multiple system atrophy. Arch Neurol 64: 545–551.
9. Plante-Bordeneuve V, Bandmann O, Wenning G, Quinn NP, Daniel SE, et al.
(1995) CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple
system atrophy. Mov Disord 10: 277–278.
10. Cairns NJ, Atkinson PF, Kovacs T, Lees AJ, Daniel SE, et al. (1997)
Apolipoprotein E e4 allele frequency in patients with multiple system atrophy.
Neurosci Lett 221: 161–164.
11. Ozawa T, Takano H, Onodera O, Kobayashi H, Ikeuchi T, et al. (1999) No
mutation in the entire coding region of the alpha-synuclein gene in
pathologically confirmed cases of multiple system atrophy. Neurosci Lett 270:
110–112.
12. Morris HR, Vaughan JR, Datta SR, Bandopadhyay R, Rohan De Silva HA, et
al. (2000) Multiple system atrophy/progressive supranuclear palsy: alpha-
Synuclein, synphilin, tau, and APOE. Neurology 55: 1918–1920.
13. Nishimura M, Kawakami H, Komure O, Maruyama H, Morino H, et al. (2002)
Contribution of the interleukin-1beta gene polymorphism in multiple system
atrophy. Mov Disord 17: 808–811.
14. Cho S, Kim CH, Cubells JF, Zabetian CP, Hwang DY, et al. (2003) Variations
in the dopamine beta-hydroxylase gene are not associated with the autonomic
disorders, pure autonomic failure, or multiple system atrophy. Am J Med
Genet A 120A: 234–236.
15. Combarros O, Infante J, Llorca J, Berciano J (2003) Interleukin-1A (-889)
genetic polymorphism increases the risk of multiple system atrophy. Mov Disord
18: 1385–1386.
16. Furiya Y, Hirano M, Kurumatani N, Nakamuro T, Matsumura R, et al. (2005)
Alpha-1-antichymotrypsin gene polymorphism and susceptibility to multiple
system atrophy (MSA). Brain Res Mol Brain Res 138: 178–181.
17. Infante J, Llorca J, Berciano J, Combarros O (2005) Interleukin-8, intercellular
adhesion molecule-1 and tumour necrosis factor-alpha gene polymorphisms and
the risk for multiple system atrophy. J Neurol Sci 228: 11–13.
18. Nishimura M, Kuno S, Kaji R, Kawakami H (2005) Brain-derived neurotrophic
factor gene polymorphisms in Japanese patients with sporadic Alzheimer’s
disease, Parkinson’s disease, and multiple system atrophy. Mov Disord 20:
1031–1033.
19. Ozawa T, Healy DG, Abou-Sleiman PM, Ahmadi KR, Quinn N, et al. (2006)
The alpha-synuclein gene in multiple system atrophy. J Neurol Neurosurg
Psychiatry 77: 464–467.
20. Soma H, Yabe I, Takei A, Fujiki N, Yanagihara T, et al. (2008) Associations
between multiple system atrophy and polymorphisms of SLC1A4, SQSTM1,
and EIF4EBP1 genes. Mov Disord 23: 1161–1167.
21. Scholz SW, Houlden H, Schulte C, Sharma M, Li A, et al. (2009) SNCA
variants are associated with increased risk for multiple system atrophy. Ann
Neurol 65: 610–614.
22. Pals P, Lincoln S, Manning J, Heckman M, Skipper L, et al. (2004) alpha-
Synuclein promoter confers susceptibility to Parkinson’s disease. Ann Neurol 56:
591–595.
23. Mellick GD, Maraganore DM, Silburn PA (2005) Australian data and meta-
analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for
Parkinson’s disease. Neurosci Lett 375: 112–116.
24. Chiba-Falek O, Touchman JW, Nussbaum RL (2003) Functional analysis of
intra-allelic variation at NACP-Rep1 in the alpha-synuclein gene. Hum Genet
113: 426–431.
25. Marchini J, Howie B, Myers S, McVean G, Donnelly P (2007) A new multipoint
method for genome-wide association studies by imputation of genotypes. Nat
Genet 39: 906–913.
26. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet 81: 559–575.
27. Yabe I, Soma H, Takei A, Fujiki N, Yanagihara T, et al. (2006) MSA-C is the
predominant clinical phenotype of MSA in Japan: analysis of 142 patients with
probable MSA. J Neurol Sci 249: 115–121.
SNCA Is Associated with MSA
PLoS ONE | www.plosone.org 6 September 2009 | Volume 4 | Issue 9 | e7114
